{"id":54793,"date":"2023-03-14T08:04:19","date_gmt":"2023-03-14T07:04:19","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/algotx-raises-e20m-to-conduct-atx01s-phase-2-program-in-peripheral-neuropathic-pain\/"},"modified":"2023-03-14T08:04:19","modified_gmt":"2023-03-14T07:04:19","slug":"algotx-raises-e20m-to-conduct-atx01s-phase-2-program-in-peripheral-neuropathic-pain","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/algotx-raises-e20m-to-conduct-atx01s-phase-2-program-in-peripheral-neuropathic-pain\/","title":{"rendered":"AlgoTx Raises \u20ac20M to Conduct ATX01\u2019s Phase 2 Program in Peripheral Neuropathic Pain"},"content":{"rendered":"
\n

SURESNES, France–(BUSINESS WIRE)–European biotech AlgoTx, the developer of first-in-class treatment ATX01 for chemotherapy-induced peripheral neuropathy (CIPN), announced today the success of a \u20ac20M Series B fundraising led by Relyens Innovation Sant\u00e9 \/ Turenne Capital , followed by UI Investissement, and historical investors Bpifrance through its Innobio 2 fund and Omnes Capital. Early and new business angel investors also significantly participated in this financing round, and AlgoTx secured an additional 1M\u20ac in non-dilutive financing. The proceeds will be used to demonstrate the clinical efficacy of ATX01 in neuropathic pain.\n<\/p>\n

<\/a><\/p>\n

\nBervin Bouani<\/b>, Investment Director at Turenne Capital, commented: \u201cWe are very proud to lead this strategic financing round to support AlgoTx to continue the clinical development of ATX01 lead candidate that has the potential to significantly improve the lives of patients with neuropathic pain. We look forward to working with St\u00e9phane and his outstanding team to transform AlgoTx into a global pain player.\u201d<\/i>\n<\/p>\n

\nFollowing the demonstration of ATX01\u2019s early clinical safety and low systemic passage in Phase 1, the Phase 2 \u201cACT\u201d study will now assess ATX01\u2019s ability to reduce pain in adult CIPN patients \u2013 a program granted \u201cfast-track\u201d designation by FDA. In parallel, the Phase 2 \u201cEASE\u201d study will explore ATX01\u2019s efficacy in the debilitating pain of erythromelalgia, a program for which ATX01 was granted \u201cOrphan Disease Designation\u201d in the US and Europe.\n<\/p>\n

\nSt\u00e9phane Thiroloix<\/b>, Founder & CEO of AlgoTx, says: \u201cIt is incredibly exciting to start the efficacy trials of ATX01, supported by such a high-profile syndicate of investors. We look forward to enrolling patients in our studies any day now.\u201d<\/i>\n<\/p>\n

\nOver half of cancer patients treated with chemotherapy develop CIPN and experience sensory symptoms and pain in the hands and feet: loss of sensitivity, tingling, burning, cold and intense pain can persist for months to years after treatment. It affects over two million patients in the US and Europe and represents a leading cause for modification or interruption of chemotherapy. To this date, no therapeutic approach has offered a satisfactory response for patients and their caregivers, oncologists, neurologists and pain specialists.\n<\/p>\n

\n\u00ab We are very pleased to support the AlgoTx team in the development of ATX01, driven by our belief in its significant impact in the treatment of CIPN and other neuropathic pain. AlgoTx can truly transform the lives of patients suffering from these conditions \u00bb, <\/i>says Pauline de Breteuil<\/b> Senior Partner UI Investissement \/ FCPI Majycc Innovation Sant\u00e9.\n<\/p>\n

\nAbout AlgoTx
\n
<\/b>AlgoTx develops novel treatments for complex pain, with lead program ATX01 in Phase 2 in chemotherapy-induced peripheral neuropathy (NCT05593614) and erythromelalgia. More information at www.algotx.com<\/a>
ACT study : ATX01 for the pain of ChemoTherapy, (NCT05593614). EASE study : Efficacy of ATX01 \/ Study in Erythromelalgia.\n<\/p>\n

\nABOUT TURENNE GROUP\/RELYENS INNOVATION SANT\u00c9
\n
<\/b>Launched in 2014, Relyens Innovation Sant\u00e9<\/b> is is an evergreen venture capital vehicle specializing in health innovation controlled and owned by Relyens, a mutual insurance company specializing in the risk management of health, social and medical players. Relyens is the leading French player in medical civil liability. Advised by Turenne Sant\u00e9 (Health Division of Turenne Group), Relyens Innovation Sant\u00e9’s mission is to support the growth and development phases of innovative companies in the health sector.
\n
Turenne Group<\/b>, one of the leading private equity companies in France, has been supporting entrepreneurs for 23 years in their company\u2019s innovation, development and transfer projects. As an independent player, the Group has assets of \u20ac1.4 billion under management. Its teams, made up of 68 professionals, including 52 investors, based in Paris, Lille (Nord Capital Partenaires), Lyon, Bordeaux, Marseille, Nice and Metz, support 290 business leaders, particularly in the healthcare, hospitality, innovation, BtoB services, and in the digital and impact sectors. With more than \u20ac300m, our healthcare team (Turenne Sant\u00e9) invests across the entire value creation chain for healthcare companies through various investment approaches.
\n
For more information: www.relyens.eu\/fr<\/a> \/ www.turennecapital.com<\/a>\n<\/p>\n

\nAbout Bpifrance and InnoBio 2
\n
<\/b>Bpifrance is the French national investment bank: it finances businesses \u2013 at every stage of their development \u2013 through loans, guarantees, equity investments and export insurances. Bpifrance also provides extra financial services (training, consultancy) to help entrepreneurs meet their challenges (innovation, export).
\n
InnoBio 2 is an investment fund dedicated to life sciences, managed by Bpifrance, which is also one of the LPs alongside Sanofi, Boehringer Ingelheim, Takeda, Ipsen, Servier, BMS, European Investment Fund and Pasteur Mutualit\u00e9. InnoBio 2, with \u20ac203 million, aims to invest in companies developing innovative products and services, close to or in early clinical development, with the objective of bringing them until the clinical proof of concept. InnoBio 2 takes minority equity stake in companies and can lead or co-lead the investment rounds.
\n
For more information, please visit: www.bpifrance.com<\/a> \u2013 Follow us on Twitter : @bpifrance – @BpifrancePresse\n<\/p>\n

\nAbout Omnes
\n
<\/b>Omnes is a leading Paris-based European investor in private equity and infrastructure. With more than \u20ac5 billion in assets under management, Omnes provides companies with the equity capital they need to grow through its four core businesses: Venture Capital, Buyout & Growth Capital, Infrastructure and Co-Investment. With more than 30 trade sales and nearly 15 IPOs in 20 years (including Themis Bioscience, Biovex, arGEN-X, Novaled and Direct Energie), Omnes Venture Capital team is a leading French player in financing innovative SMEs with dual expertise in the deep-tech and healthcare sectors. Omnes is committed to ESG issues and has set up the Omnes Foundation in aid of children\u2019s charities. The company is also a signatory to the United Nations Principles for Responsible Investment (PRI). www.omnescapital.com<\/a>\n<\/p>\n

\nAbout UI Investissement
\n
<\/b>UI Investissement is an independent, specialized company in the development of unlisted French companies with \u20ac1.5 billion under management. For over 50 years, UI Investissement has been committed to work alongside the managers of growing SMEs and STIs to help them emerge as economically and sustainably successful businesses through its focus on three areas: health, agro-business, and business services.
\n
With its expertise, UI Investissement provides support to companies in the health sector at all stages of their development and plays a central role in the ecosystem. It is through the Majycc Innovation Sant\u00e9 fund that UI Investissement supports entrepreneurs who aim to be the architects of tomorrow’s health. The roots of Majycc Innovation Sant\u00e9 are deeply connected to the DNA of several private clinic groups, nursing home groups, and mutual health insurance companies, representing entrepreneurship, health and human values, respect for corporate culture, and the projects of the individuals who build them.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nPress<\/b>
AlgoTx : <\/b>Genevi\u00e8ve Cliquet Consultant : contact@cliquet-consultant.com<\/a> <\/span>+33(0) 607 500 567
\n
Turenne Capital : <\/b>Sandra Capela <\/b>: scapela@turennecapital.com<\/a> ; Agence TADEO, Louis Branger louis.branger@taddeo.fr<\/a> – 06 76 23 52 85
\n
Bpifrance <\/b>: Juliette Fontanillas : juliette.fontanillas@bpifrance.fr<\/a>
Omnes Capital: <\/b>Yanie de Nadaillac : yanie.de-nadaillac@omnescapital.com<\/a> – +33(0) 7 63 13 65 74
\n
UI Investissement : Laurent Maillard <\/b>laurentmaillard.pro@gmail.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SURESNES, France–(BUSINESS WIRE)–European biotech AlgoTx, the developer of first-in-class treatment ATX01 for chemotherapy-induced peripheral neuropathy (CIPN), announced today the success of a \u20ac20M Series B fundraising led by Relyens Innovation Sant\u00e9 \/ Turenne Capital , followed by UI Investissement, and historical investors Bpifrance through its Innobio 2 fund and Omnes Capital. Early and new business … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-54793","6":"format-standard","7":"category-industry"},"yoast_head":"\nAlgoTx Raises \u20ac20M to Conduct ATX01\u2019s Phase 2 Program in Peripheral Neuropathic Pain - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/algotx-raises-e20m-to-conduct-atx01s-phase-2-program-in-peripheral-neuropathic-pain\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AlgoTx Raises \u20ac20M to Conduct ATX01\u2019s Phase 2 Program in Peripheral Neuropathic Pain - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SURESNES, France–(BUSINESS WIRE)–European biotech AlgoTx, the developer of first-in-class treatment ATX01 for chemotherapy-induced peripheral neuropathy (CIPN), announced today the success of a \u20ac20M Series B fundraising led by Relyens Innovation Sant\u00e9 \/ Turenne Capital , followed by UI Investissement, and historical investors Bpifrance through its Innobio 2 fund and Omnes Capital. Early and new business ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/algotx-raises-e20m-to-conduct-atx01s-phase-2-program-in-peripheral-neuropathic-pain\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-14T07:04:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230314005169\/en\/1736891\/21\/Capture_d%E2%80%99%C3%A9cran_2023-03-13_%C3%A0_16.41.41.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/algotx-raises-e20m-to-conduct-atx01s-phase-2-program-in-peripheral-neuropathic-pain\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/algotx-raises-e20m-to-conduct-atx01s-phase-2-program-in-peripheral-neuropathic-pain\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"AlgoTx Raises \u20ac20M to Conduct ATX01\u2019s Phase 2 Program in Peripheral Neuropathic Pain\",\"datePublished\":\"2023-03-14T07:04:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/algotx-raises-e20m-to-conduct-atx01s-phase-2-program-in-peripheral-neuropathic-pain\\\/\"},\"wordCount\":1116,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/algotx-raises-e20m-to-conduct-atx01s-phase-2-program-in-peripheral-neuropathic-pain\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230314005169\\\/en\\\/1736891\\\/21\\\/Capture_d%E2%80%99%C3%A9cran_2023-03-13_%C3%A0_16.41.41.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/algotx-raises-e20m-to-conduct-atx01s-phase-2-program-in-peripheral-neuropathic-pain\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/algotx-raises-e20m-to-conduct-atx01s-phase-2-program-in-peripheral-neuropathic-pain\\\/\",\"name\":\"AlgoTx Raises \u20ac20M to Conduct ATX01\u2019s Phase 2 Program in Peripheral Neuropathic Pain - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/algotx-raises-e20m-to-conduct-atx01s-phase-2-program-in-peripheral-neuropathic-pain\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/algotx-raises-e20m-to-conduct-atx01s-phase-2-program-in-peripheral-neuropathic-pain\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230314005169\\\/en\\\/1736891\\\/21\\\/Capture_d%E2%80%99%C3%A9cran_2023-03-13_%C3%A0_16.41.41.jpg\",\"datePublished\":\"2023-03-14T07:04:19+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/algotx-raises-e20m-to-conduct-atx01s-phase-2-program-in-peripheral-neuropathic-pain\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/algotx-raises-e20m-to-conduct-atx01s-phase-2-program-in-peripheral-neuropathic-pain\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/algotx-raises-e20m-to-conduct-atx01s-phase-2-program-in-peripheral-neuropathic-pain\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230314005169\\\/en\\\/1736891\\\/21\\\/Capture_d%E2%80%99%C3%A9cran_2023-03-13_%C3%A0_16.41.41.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230314005169\\\/en\\\/1736891\\\/21\\\/Capture_d%E2%80%99%C3%A9cran_2023-03-13_%C3%A0_16.41.41.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/algotx-raises-e20m-to-conduct-atx01s-phase-2-program-in-peripheral-neuropathic-pain\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AlgoTx Raises \u20ac20M to Conduct ATX01\u2019s Phase 2 Program in Peripheral Neuropathic Pain\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AlgoTx Raises \u20ac20M to Conduct ATX01\u2019s Phase 2 Program in Peripheral Neuropathic Pain - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/algotx-raises-e20m-to-conduct-atx01s-phase-2-program-in-peripheral-neuropathic-pain\/","og_locale":"en_US","og_type":"article","og_title":"AlgoTx Raises \u20ac20M to Conduct ATX01\u2019s Phase 2 Program in Peripheral Neuropathic Pain - Pharma Trend","og_description":"SURESNES, France–(BUSINESS WIRE)–European biotech AlgoTx, the developer of first-in-class treatment ATX01 for chemotherapy-induced peripheral neuropathy (CIPN), announced today the success of a \u20ac20M Series B fundraising led by Relyens Innovation Sant\u00e9 \/ Turenne Capital , followed by UI Investissement, and historical investors Bpifrance through its Innobio 2 fund and Omnes Capital. Early and new business ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/algotx-raises-e20m-to-conduct-atx01s-phase-2-program-in-peripheral-neuropathic-pain\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-14T07:04:19+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230314005169\/en\/1736891\/21\/Capture_d%E2%80%99%C3%A9cran_2023-03-13_%C3%A0_16.41.41.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/algotx-raises-e20m-to-conduct-atx01s-phase-2-program-in-peripheral-neuropathic-pain\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/algotx-raises-e20m-to-conduct-atx01s-phase-2-program-in-peripheral-neuropathic-pain\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"AlgoTx Raises \u20ac20M to Conduct ATX01\u2019s Phase 2 Program in Peripheral Neuropathic Pain","datePublished":"2023-03-14T07:04:19+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/algotx-raises-e20m-to-conduct-atx01s-phase-2-program-in-peripheral-neuropathic-pain\/"},"wordCount":1116,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/algotx-raises-e20m-to-conduct-atx01s-phase-2-program-in-peripheral-neuropathic-pain\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230314005169\/en\/1736891\/21\/Capture_d%E2%80%99%C3%A9cran_2023-03-13_%C3%A0_16.41.41.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/algotx-raises-e20m-to-conduct-atx01s-phase-2-program-in-peripheral-neuropathic-pain\/","url":"https:\/\/pharma-trend.com\/en\/algotx-raises-e20m-to-conduct-atx01s-phase-2-program-in-peripheral-neuropathic-pain\/","name":"AlgoTx Raises \u20ac20M to Conduct ATX01\u2019s Phase 2 Program in Peripheral Neuropathic Pain - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/algotx-raises-e20m-to-conduct-atx01s-phase-2-program-in-peripheral-neuropathic-pain\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/algotx-raises-e20m-to-conduct-atx01s-phase-2-program-in-peripheral-neuropathic-pain\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230314005169\/en\/1736891\/21\/Capture_d%E2%80%99%C3%A9cran_2023-03-13_%C3%A0_16.41.41.jpg","datePublished":"2023-03-14T07:04:19+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/algotx-raises-e20m-to-conduct-atx01s-phase-2-program-in-peripheral-neuropathic-pain\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/algotx-raises-e20m-to-conduct-atx01s-phase-2-program-in-peripheral-neuropathic-pain\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/algotx-raises-e20m-to-conduct-atx01s-phase-2-program-in-peripheral-neuropathic-pain\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230314005169\/en\/1736891\/21\/Capture_d%E2%80%99%C3%A9cran_2023-03-13_%C3%A0_16.41.41.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230314005169\/en\/1736891\/21\/Capture_d%E2%80%99%C3%A9cran_2023-03-13_%C3%A0_16.41.41.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/algotx-raises-e20m-to-conduct-atx01s-phase-2-program-in-peripheral-neuropathic-pain\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"AlgoTx Raises \u20ac20M to Conduct ATX01\u2019s Phase 2 Program in Peripheral Neuropathic Pain"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54793","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=54793"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54793\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=54793"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=54793"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=54793"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}